Dr. Glaspy on Immunotherapy in Endometrial Cancer

Dr. Levine on Immunotherapy in Endometrial CancerПодробнее

Assessing chemotherapy and immunotherapy in dMMR endometrial cancerПодробнее

Transforming Second-Line Immunotherapy for Endometrial CancerПодробнее

Current treatment options in advanced/recurrent endometrial cancerПодробнее

Dr. Glaspy on Immunogenicity in Ovarian CancerПодробнее

Improving responses to immunotherapy for patients with endometrial cancerПодробнее

Immunotherapy in Endometrial Cancer: Expanding HorizonsПодробнее

What is the Role of Immunotherapy in Endometrial Cancer?Подробнее

Immunotherapy as a Treatment Cornerstone for Advanced Endometrial CancerПодробнее

Latest developments in immunotherapy for advanced/recurrent endometrial cancerПодробнее

Precision oncology in endometrial cancerПодробнее

Zoptarelin no better than doxarubicin for second-line advanced endometrial cancerПодробнее

Endometrial Cancer Health Outcomes: pembrolizumab for patients with MSI-high endometrial cancerПодробнее

New immunotherapy for endometrial cancer patients | OSUCCC – JamesПодробнее

Research priorities for metastatic endometrial cancerПодробнее

Dr. Powell on MSI and dMMR as Potential Biomarkers in Endometrial CancerПодробнее

Treating Endometrial Cancer With ImmunotherapyПодробнее

Incorporating immunotherapy in cervical cancer and endometrial cancer treatment: 2022 ESMO FloridaПодробнее

Dr. Makker Discusses Immunogenicity in Endometrial CancerПодробнее